

China Macro Flash

Data for 1Q May Confirm a Modest Recovery and Benign Inflation

■ Growth may have stayed close to 8% alleviating short-term inflation concerns

– Official PMI increased from 50.1 in Feb to 50.9 in Mar, but the improvement paled in comparison with the historical pattern. The sentiment index remained in the 50-51 range in the past six months, suggesting slow expansion of manufacturing activity. IP may have grown by 10.2%YoY in 1Q, consistent with GDP growth of around 8%YoY. The modest recovery has helped to contain commodity prices, and CPI inflation may have stayed below 2.5%YoY in 1Q. Abundant liquidity and credit at present may continue to sustain growth momentum in 2Q, but growth may head down in 2H as the easing bias of policies is gradually removed. We maintain our annual growth forecast of 7.8%.

■ CPI inflation likely fell to 2.1%YoY due to a post-holiday price decline

– The MOC and NBS data both pointed to a sharp decline in food prices after the Chinese New Year. Overall price level may have decreased by 0.9%MoM, and YoY inflation likely dropped sharply from 3.2% in Feb to 2.1% in Mar. PPI deflation may have intensified from -1.6%YoY in Feb to -2.2% in Mar, further reducing inflationary pressures. CPI inflation will likely exhibit an upward trend from 2Q, but excess capacity and generally weak domestic recovery should help keep CPI inflation below 3%YoY in 2Q, thus reducing the prospect of an immediate policy tightening.

■ Net export may have offset the weakness in consumption

– Relative to 4Q12, investment growth appears to be stable, but consumption growth has suffered from the government campaign to cut wasteful spending. Trade surplus surprised significantly on the upside, suggesting external demand has contributed positively to growth. IP growth may have accelerated from 9.9%YoY in Jan-Feb to 10.6%YoY in March (10.2%YTD), reflecting increased production activity after the holiday. YTD FAI growth likely slowed from 21.2% in Jan-Feb to 20.9%YoY in March, reflecting slightly tighter credit conditions and intensification of PPI deflation. We estimate a rebound in retail sales growth from 12.3%YoY in Feb to 13.5% in Mar (12.7%YTD) based on the surge in property sales, which may have boosted sales of building materials, furniture, household electronics and cars.

■ M2 growth may have fallen to 14.5% and new credit risen to Rmb850bn

– PBOC appears to have intervened actively in the FX market to slow the pace of RMB appreciation, expanding the monetary base. Meanwhile, the central bank is mopping up excess liquidity through repos in order to bring down broad money growth to the annual target of 13%. M2 growth may have fallen from 15.2%YoY in Feb to 14.5%YoY in Mar reflecting the net impact of these operations. Based on PBOC's preferred distribution of loans among the quarters, as well as reported new lending by the biggest banks in the first 24 days of the month, we estimate that new RMB lending may have reached 850bn in Mar.

Shuang Ding

+852-2501-2769
shuang.ding@citi.com

Enjiang Cheng

+86-10-5937-6038
enjiang.cheng@citi.com

Minggao Shen

+852-2501-2485
minggao.shen@citi.com

Serena Wang

serena.wang@citi.com

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Not for distribution in the People's Republic of China, excluding the Hong Kong Special Administrative Region.

Data for 1Q May Confirm a Modest Recovery and Benign Inflation

Figure 1. Economic Data Release for March / 1Q 2013

	Date	For	Citi Fcst*	Mkt Fcst	Prev
CPI (% YoY)	9-Apr	Mar	2.1 (2.4)	2.5	3.2
PPI (% YoY)			-2.2 (-1.8)	-1.7	-1.6
Trade Balance (\$bn)	10-Apr	Mar	15.00	15.40	15.23
Exports (YoY%)			11.8 (19.0)	10.1	21.8
Imports (YoY%)			6.2 (5.5)	4.2	-15.2
M0 Supply (%YoY)	10~15-Apr	Mar	11.2	13.0	17.2
M1 Supply (%YoY)			8.0	9.8	9.5
M2 Supply (%YoY)			14.5	14.2	15.2
New Yuan Loans (RMB bn)			850	875.0	620.0
GDP	15-Apr	1Q	8.0	8.0	7.9
IP (% YoY)		Mar	10.6 (10.2)	10.0	9.9
Retail Sales (% YoY)			13.5 (12.7)	12.6	12.3
FAI - urban (% YoY ytd)			20.9	21.3	21.2

Note: *YoY growth for 1Q in parenthesis

Source: Bloomberg and Citi Research

Apr 9,

CPI

Headline: 2.1%YoY

Food: 3.4%YoY

Nonfood: 1.5%YoY

CPI inflation likely fell to 2.1%YoY due to a post-holiday price decline –

Consumer prices rose 1.1%MoM and 3.2%YoY in Feb as a result of seasonal price increases during the Chinese New Year. As expected, prices (especially food prices) fell after the holidays, easing concerns over inflation.

- Food inflation likely dropped to 3.4%YoY from 6.0%YoY in Feb. Interim data from the Ministry of Commerce (mostly wholesale prices) showed that food prices fell almost across the board, with average meat, fish and vegetable prices declining 2.1%, 2.2% and 12.3%MoM. The NBS interim data (mostly retail prices) showed even faster price declines. As CPI inflation is more related to retail prices, we assign a heavy weight to the NBS data, and estimate that food prices fell by 2.3%MoM, and rose 3.4%YoY.
- Non-food inflation may have fallen to 1.5%YoY from 1.9%YoY in Feb. The fuel prices were cut by about 3.5% on Mar 27, effectively reversing the price hike on Feb 25, but the impact on inflation should be very limited for Mar. Seasonally, non-food prices tend to decline in Mar, and we estimate that non-food prices declined by 0.1%MoM also reflecting the post-holiday effect. The base effect would take another 0.3ppt off, bringing non-food inflation to 1.5%YoY in Mar.
- Overall price level may have decreased by 0.9%MoM, and YoY inflation likely dropped sharply from 3.2% in Feb to 2.1% in Mar. Quarterly inflation may have increased to 2.4%YoY from 2.1%YoY in 4Q12.
- CPI inflation will likely exhibit an upward trend following volatilities associated with the Chinese New year in 1Q. However, excess capacity in the manufacturing sector and generally weak domestic recovery should prevent inflation from becoming a threat, as long as PPI deflation continues. CPI inflation is likely to stay below 3%YoY in 2Q, and rise to around 3.5% by year-end, taking into account the effects of possible price reforms.

Apr 9,


PPI

Headline: -2.2%YoY

PPI deflation may have intensified to -2.2%YoY – The international commodity prices as measured by the CRB index declined by about 1.6%MoM. Interim data from the Ministry of Commerce showed that producer good prices for raw materials generally declined during the month, especially for mineral products (about -2%), non-ferrous metal (about -1.8%) and rubber (about -4.8%). The PMI input price index fell by 4.9ppts although it stayed above 50 at 50.6 in Mar. Based on the


relationship between PPI and MOC interim data, we estimate the overall PPI may have dropped by 0.3%MoM, and YoY deflation likely intensified from -1.6% to -2.2%, as the base effect removed roughly 0.3ppt from the YoY inflation. Quarterly deflation may have eased to -1.8%YoY from -2.3%YoY in 4Q12.

Figure 2. CPI inflation likely fell to 2.1%YoY due to post-holiday effect



Source: NBS and Citi Research

Figure 3. PPI deflation may have intensified to -2.2%YoY



Source: NBS, Bloomberg and Citi Research

Apr 15,
Industrial Value Added
Headline: 10.6%YoY

Industrial production (IP) growth may have risen to 10.6%YoY – Both the official and HSBC manufacturing PMI stayed in the expansionary territory and increased in March. However, the improvement of the official PMI in Mar (0.8ppt) was significantly smaller than the average increase for Mar since 2005 (roughly 3ppts), and the index has been in the 50-51 range in the past six months, indicating the recovery of the manufacturing activity has been lackluster. The official PMI production index increased by 1.5ppts in Mar, also weaker than the average improvement for Mar (roughly 5ppts). Meanwhile, the PBOC 1Q survey shows that entrepreneurs and bankers both feel the economy is warming up, with economic heat index and confidence index higher than 4Q12. We estimate that IP growth may have accelerated from 9.9%YoY in Jan-Feb to 10.6%YoY in March. For 1Q, IP may have grown 10.2%YoY, relative to 10.0%YoY in 4Q12.

Apr 15,
Urban FAI, YTD
Headline: 20.9%YoY

YTD Fixed asset investment (FAI) growth may have slowed to 20.9% YoY – FAI growth rose from 20.6% in 2012 to 21.2%YoY in Jan-Feb 2013, facilitated mainly by favorable funding conditions including budget funding and bank credit especially in Jan. Money and credit growth slowed in Feb, and is likely to slow further in Mar, and CBRC has introduced more regulations on wealth management products, which could slow the expansion of the shadow banking credit. On the other hand, property investment appears to be supported by increased sales volume. We estimate a retreat of YTD FAI growth from 21.2% in Jan-Feb to 20.9%YoY in March, reflecting slightly tighter credit conditions and intensification of PPI deflation.

Apr 15,
Retail Sales
Headline: 13.5%YoY

Retail sales may have accelerated to 13.5%YoY in March – Nominal retail sales growth decelerated from 15.2%YoY in Dec 2012 to 12.3% in Jan-Feb, mainly due to the curb on government lavishing spending. The PBOC 1Q depositor survey shows employment index and current income index further improved, which should help maintain healthy private consumption growth. We estimate a rebound in retail sales based on the surge in property sales which may have boosted sales of building materials, furniture, household electronics and cars. However, lower CPI inflation in Mar relative to Feb may have prevented a more significantly acceleration. Quarterly retail sales may have grown by 12.7%YoY, compared with 14.5%YoY in 4Q12.


Apr 15

Real GDP

Headline: 8.0%YoY


Growth likely accelerated slightly to 8%YoY in 1Q – Relative to 4Q12, investment growth appears to be stable as reflected in the FAI data at the beginning of the year. Consumption growth, on the other hand, may have slowed as a result of the government campaign to cut wasteful spending and crack down on corruption. However, trade surplus reached \$44bn in Jan-Feb, compared with a deficit of \$4bn for the same period last year, suggesting net export (external demand) may have contributed positively to growth and offset the weakness in consumption in 1Q. Based on the correlation between GDP and its production components (especially IP), we estimate that growth quickened from 7.9%YoY in 4Q12 to 8.0% in 1Q.

Figure 4. Growth likely accelerated slightly to 8.0%YoY in 1Q



Source: CEIC and Citi Research

Figure 6. YTD FAI growth may have fallen slightly to 20.9% due to slightly tighter credit condition



Source: CEIC and Citi Research

Figure 5. IP growth may have accelerated to 10.6%YoY in Mar



Source: CEIC and Citi Research

Figure 7. Retail sales growth may have accelerated due to rising home sales



Source: CEIC and Citi Research

Apr 10,

Trade

Balance: \$15.0bn


Exports: 11.8%YoY

Imports: 6.2%YoY

Export growth may have slowed reflecting weak export order – China's export growth accelerated from 9.4%YoY in 4Q12 to 23.6% in Jan-Feb and import growth accelerated from 2.8%YoY in 4Q12 to 5.1% in Jan-Feb. We think it would be difficult to sustain the Jan-Feb export growth, given the weak international demand and uncertainty in EU countries. PMI new export order index stayed below 50 in Jan-Feb (48.5 and 47.3 respectively) and the rebound in Mar (3.6ppts) was milder than the average for Mar since 2005 (4.5ppts). Other indicators, including growth of export cargo (7.5%YoY in Jan-Feb) and export delivery value (7.8%YoY in Jan-Feb)


indicate the export growth in Jan-Feb may have been exaggerated. We estimate export growth rate to fall from 23.6% in Jan-Feb to 11.8%YoY in March. Export may have grown by 19.0%YoY in 1Q as a result. Quarterly import growth may have continued to accelerate slowly, from 1.6%YoY in 3Q12 to 2.8%YoY in 4Q12 and 5.1%YoY in Jan-Feb, reflecting weak economic recovery. We estimate imports grew by 6.2%YoY in March, and 5.5%YoY in 1Q. Trade surplus may have reached \$15bn in Mar, and roughly \$60bn in 1Q.

Figure 8. Export growth may have slowed to 11.8%YoY in Mar



Source: CFLP, NBS and Citi Research

Figure 9. Imports may have grown 6.2%YoY in Mar



Source: China Custom, CFLP, NBS and Citi Research

Apr 10-15

Money

M0: 11.2%YoY

M1: 8.0%YoY

M2: 14.5%YoY

New RMB Loans: 850.0bn


Broad money (M2) growth may have fallen to 14.5% – In response to sizable trade surplus and renewed capital inflows, PBOC appears to be intervening actively in the FX market by purchasing FX to slow the pace of RMB appreciation. In Jan, PBOC purchased more than \$50bn. The central bank may have purchased significant amount also in Feb and Mar, expanding the monetary base. Meanwhile, PBOC has been sterilizing the liquidity created by FX purchase, in order to bring down broad money growth to the annual target of 13%. The following factors may have affected monetary growth in Mar:

- PBOC withdrew Rmb153bn of liquidity, on a net basis, from the banking system through open market operations.
- Trade account may have run a surplus of about \$15bn, and the net FDI inflows and other capital inflows may have continued. We assume that PBOC purchased \$20bn FX during the month.
- Government deposits at the PBOC may have declined by about Rmb400bn in Mar, as government spending tends to accelerate in Mar. This is equivalent to liquidity injection.
- Taking these factors into consideration, M2 growth may have fallen from 15.2%YoY in Feb to 14.5%YoY in Mar. M1 growth may have slowed to 8.0%YoY, consistent with a modest economic recovery in 1Q. M0 growth may have normalized to 11.2%YoY.

New RMB lending may have increased to Rmb850bn – The pace of credit extension in Jan-Feb appears to be in line with our estimated annual loan quota of Rmb8.5tn. The PBOC's monetary policy report for 2012 indicates that the central bank favors the distribution of annual loans among the four quarters at the ratio of 3:3:2:2. Based on this ratio as well as reported new lending by the biggest banks in


the first 24 days of the month, we estimate that new RMB lending may have reached 850bn, implying total credit in 1Q of Rmb2.54tn.

Figure 10. PBOC withdrew liquidity through OMOs in Mar



Source: PBOC and Citi Research

Figure 11. Historical distribution of annual loans implies an increase in new lending in Mar



Source: PBOC and Citi Research

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of China.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from China.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from China.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from China in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): China.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: China.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, non-securities-related: China.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Asia

Shuang Ding; Minggao Shen; Serena Wang

Citibank (China) Co. Ltd.

Enjiang Cheng

OTHER DISCLOSURES

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The

Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers: Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Research research report. Ask your Financial Advisor or use smithbarney.com to view any available Morgan Stanley research reports in addition to Citi Research research reports.

Important disclosure regarding the relationship between the companies that are the subject of this Citi Research research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

This Citi Research research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of Citi Research. This could create a conflict of interest.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in **Australia** through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A., Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No.

460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comisión Nacional Bancaria y de Valores. Reforma 398, Col. Juárez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangkok, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Büyükdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs) and other product that is made available through other distribution channels only to certain categories of clients to satisfy legal or regulatory requirements, Citi Research concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual Citi Research analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. Citi Research simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2013 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
